Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...

PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) is set to showcase groundbreaking advancements in its iPSC-derived ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Context Therapeutics (CNTX – Research Report), retaining the price ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

ADC Therapeutics SA (NYSE:ADCT ... evaluating ADCT-602 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia continues to progress and dose escalation continues at the 60 ...

FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in ...